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Induced sputum is a non-invasive sampling technique for the analysis of airway inflammation in
various lung diseases and comprises valuable potential for the identification of biomarkers and
therapeutic targets by molecular methods. In the context of biobanking with preservation of
induced sputum samples for subsequent analyses we applied the HEPES-glutamic acid
buffer-mediated organic solvent protection effect (HOPE)-technique for preparation of
induced sputum samples.
Induced sputum samples of 20 patients with moderate to severe chronic obstructive pulmo-
nary disease (COPD) and 12 healthy controls were collected. Cell pellets of induced sputum
samples were preserved with HOPE and subsequently embedded in paraffin. Immunostaining
of paraffin-block sections for interleukin-8, interleukin-17, myeloperoxidase,
matrixmetalloproteinase-9, CD68, and CD8 revealed distinct signals without antigen retrieval.
Moreover, RNA was extracted and successfully used for transcription microarray analysis.Research Institute at Hospital Grosshansdorf, Center for Pneumology and Thoracic Surgery,
dorf, Germany. Tel.: þ49 4102 601 2416; fax: þ49 4102 8881 114.
research.de (F. Pedersen).
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588 F. Pedersen et al.Sputum samples preserved by the HOPE-technique display a tool to address scientific
approaches in pulmonary research, which can enable the identification of new biomarkers
and therapeutic targets in respiratory diseases.
ª 2012 Elsevier Ltd. All rights reserved.Introduction Induced sputum samples of matched healthy non-smokersInduced sputum is recognized as a valuable sampling
method for both research and clinical use in chronic airway
diseases such as chronic obstructive pulmonary disease
(COPD), asthma, and cystic fibrosis.1e3 It is widely used to
assess airway inflammation by means of differential cell
count analysis as well as analysis of proteins in sputum
supernatant following sample processing.4,5 Also molecular
techniques for RNA and microRNA analyses are increasingly
applied on induced sputum samples of patients with
COPD.6,7 In this context, frozen samples of induced sputum
are mostly used. Further confirmatory analyses like real-
time PCR and immunohistochemistry are often performed
on a different set of samples6 due to the fact that long-term
freezing leads to deterioration of sample quality.8 Also the
commonly performed paraformaldehyde (PFA) fixation is
not a satisfactory alternative since proteins lose their
antigenic properties.9 Thus, a molecular-biological analysis
of the samples is difficult. The acetone-methanol fixation is
also inappropriate since morphological changes result due
to dehydration and shrinkage of the cells.10 In contrast,
preservation with the HEPES-glutamic acid buffer-mediated
organic solvent protection effect (HOPE)etechnique has
been shown to represent an improved method for detecting
prognostic and diagnostic biomarkers by molecular-
biological techniques including in situ hybridization,
northern blotting, or western blotting even after years of
storage.9,11e14 The prevention of protein cross-linking and
nucleic acid degradation are advantages of the HOPE-
technique.12,15 Recently, we have shown that this tech-
nique can also be applied to bronchoalveolar lavage cells,
which enables storage of the HOPE-treated bronchoalveolar
lavage samples combined with the feasibility of versatile
molecular-biological analysis.16
In the present study we applied the HOPE-technique
with subsequent paraffin-embedding to induced sputum
samples in order to improve the long-term storage of
induced sputum cells at a high quality level for the purpose
of biobanking. To evaluate this technique, sections of
paraffin-embedded induced sputum samples of COPD
patients and healthy subjects were analyzed by immuno-
cytochemistry. In addition, a transcription microarray
analysis was performed to assess the potential of this
method for further molecular research on HOPE-preserved
induced sputum samples.
Materials and methods
Patient material and study design
Induced sputum samples were obtained from patients with
moderate to severe COPD at the Pulmonary Research
Institute, Grosshansdorf, Germany. These patients were
further divided into current smokers and ex-smokers.(never-smokers or ex-smokers with a smoking history less
than five pack-years, no respiratory tract infection within
the last four weeks prior to sputum induction) served as
control. Patients with COPD had to be clinically stable with
no exacerbation or respiratory tract infection within the
four weeks prior to sputum induction. Patients with an anti-
inflammatory therapy for COPD including inhaled and oral
corticosteroids, theophylline or the phosphodiesterase-4
inhibitor Roflumilast were excluded. The study was
approved by the Ethics Committee of Medical Association
Schleswig-Holstein, Bad Segeberg, Germany (reference
number: AZ 030/11(II)). All study participants gave written
informed consent.
Induction of sputum
Sputum induction was performed as previously described.17
Briefly, patients inhaled 0.9e3% (COPD) or 3e5% (healthy)
nebulized saline solution for two consecutive periods of
5 min each through a mouth-piece with nose clip. Patients
were instructed to blow their nose, rinse their mouth and
swallow some water to minimize saliva contamination of
the expectorated sputum. The sputum was coughed up into
sterile petri dishes and cell plugs were selected immedi-
ately prior to storage at 4 C for further processing.
Processing and preservation of induced sputum
samples
Selected sputum plugs of all induction periods from each
participant were pooled, weighed, and treated with four
volumes of 6.5 mM dithiothreitol (DTT, Sputolysin; Cal-
biochem, Bad Soden, Germany) within 2 h after expecto-
ration. After 15 min incubation at room temperature four
volumes of 1 phosphate buffered saline (PBS) were added.
Subsequently, the cell suspension was filtered through
a 53 mm nylon mesh and centrifuged at 4 C and 1800 rpm
for 10 min. Supernatants were discarded and cell pellets
were re-suspended in PBS. Induced sputum cell count was
performed in a hemocytometer and viability was deter-
mined by staining with trypan blue solution (Sigma, Dei-
senhofen, Germany). An adjusted cell solution of 30,000
cells/ml was used to prepare cytospins (Cytospin II; Shan-
don Instruments, Sewickley, PA, USA). Differential cell
counts were assessed by two independent experienced
observers from 400 non-squamous cells on Giemsa stained
slides and averaged. Results were expressed as percentage
of non-squamous cells.
In order to obtain cells for preservation by the HOPE-
technique, the remaining induced sputum cell suspension
was transferred in a micro-centrifuge tube and centrifuged
for 8 min at 2500 rpm and 4 C. The supernatant was dis-
carded and 1 ml HOPE solution was added (DCS Innovative
System, Hamburg, Germany). After 16 h incubation at 4 C
HOPE-sputum 589the HOPE-treated induced sputum cell pellet was processed
as recently performed for BAL cells.16 Firstly, induced
sputum cells were centrifuged at 7200 rpm for 2 min and
the supernatant was discarded. In a following dehydration
step, the cell pellet was washed five times in 1 ml acetone
at 4 C for 30 min each. Subsequently, acetone was
removed and replaced by pre-warmed low-melting paraffin
(Polarit, DCS, Hamburg, Germany). After 16 h incubation at
54 C, the paraffin treated cell pellet was allowed to
cool down at room temperature. A cone containing the
paraffin-embedded induced sputum cells was cut off the
micro-centrifuge tube and submerged into pre-warmed,
pre-casted paraffin. HOPE-treated induced sputum cell
blocks were stored at 4 C.
To compare the cellular composition of 5 mm sections
from HOPE-treated sputum cell blocks with the cellular
composition of fresh whole cell preparations ten additional
sputum samples were analyzed. Both preparations were
stained with Giemsa stain and two independent observers
counted 400 cells of each preparation.
Immunocytochemistry
Interleukin-8, interleukin-17, myeloperoxidase, and
matrixmetalloproteinase-9 as well as the cell surface
markers CD8 and CD68 were selected for immunostaining of
HOPE-preserved induced sputum cells. The paraffin-
embedded induced sputum samples were cut on a micro-
tome (SM 2000R; Leica, Wetzlar, Germany) into 5 mm-thick
sections and mounted on Super Frost þ cover slides (Menzel
Gla¨ser, Braunschweig, Germany). Deparaffinization in iso-
propanol and blocking of endogenous peroxidases in 3%
H2O2 solution was performed as recently described for BAL
samples.16 Primary antibodies were diluted in antibody
diluent (Zytomed Systems, Berlin, Germany) and applied in
a moist chamber for 45 min (Table S1). A horseradish
peroxidase conjugated polymer kit was used for blocking
and detection according to manufacturer’s instructions
(ZytoChemHRP-Plus, Zytomed Systems, Berlin, Germany).
Negative controls were included by omission of the primary
antibody. Washing steps (3  5 min) were executed after
each reagent step with washing buffer (50 mM Tris saline
buffer containing 0.1% [v/v] Tween; pH 7.6). Amino-
ethylcarbazole (AEC, permanent AEC Kit, Zytomed Systems,
Berlin, Germany) was used as substrate for horseradish
peroxidase conjugated polymer. The color reaction was
stopped with de-mineralized water. Counterstaining was
performed by using Mayer’s Hematoxylin solution (Sigma-
eAldrich, Egham, UK) followed by dehydration at
increasing concentrations of ethanol. Finally, a xylene
treatment was carried out prior to covering the slides with
Pertex as mounting medium (Medite, Burgdorf, Germany).
Extraction of total RNA of paraffin-embedded
induced sputum samples
Total RNA extraction was performed as previously
described.16 Briefly, total RNA was extracted using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. After quantification and quality
analysis with Agilent Bioanalyzer and RNA 600 Nano Chipassay (Agilient, Bo¨blingen, Germany), RNA was stored at
80 C. The quality of RNA following preservation with
HOPE was compared with the RNA quality following
formalin-fixation and with the quality of fresh-frozen
sputum samples. Therefore, two sputum samples were
split into three portions. One portion of the sputum sample
was treated with HOPE, whereas the second portion was
fixed with formalin. The third portion was frozen immedi-
ately after processing. The formalin-fixed and fresh-frozen
samples were processed as previously described.16
Reproducibility of RNA quality was checked by process-
ing the one sputum sample in parallel three times.
Transcription microarray analysis
Total RNA samples of the three groups COPD smoker, COPD
ex-smoker, and healthy patients were pooled (supplemental
material S2). For this purpose the RNA samples were
defrosted at 4 C and 600 ng total RNA of each sample were
used, mixed and frosted quickly again. The concentration
and purity of the three pooled RNA samples were checked
before microarray analysis. Quality criteria for microarray
analyses were a RNA concentration of at least 1 mg total RNA
in 10 ml RNAse-free water. RNA purity, which was assed by
the optical density (OD) 260/280 ratio, had to be at least
1.7. The analysis was performed using an Agilent 4 44K
human whole genome array (Agilent Technologies, Wald-
bronn, Germany), including sample labeling with Cyanine 3
(Cy 3), control of labeling efficacy (NanoDrop 2000, peqlab,
Erlangen, Germany), hybridization, scanning, and primary
data analysis according to the manufacturer’s recommen-
dations (Agilent Technologies, Waldbronn, Germany). The
Raw data of the Agilent feature-extraction (scanning of the
arrays) were stored in txt-files. These data served for both,
quantile normalization and hierarchical clustering.
Quantile normalization of the signals was performed using
DirectArray software (OakLabs, Hennigsdorf, Germany). For
quality control a t-testwas applied toquantile-normed signals
andap-value<0.05wasassessedas threshold for significance.
For means of graphical illustration of the differences
between COPD smokers/COPD ex-smokers, and healthy
controls hierarchical clustering of baseline transformed data
was conducted with the GeneSpring 12 software package
(Agilent, Bo¨blingen, Germany). Compromised flags were
excluded fromclusteringanalysis andclusterswere computed
using hierarchical algorithm on both, entities and conditions.
Pearsoncentered similaritymeasureandcentroid linkage rule
were used to create dendrogram structure (Fig. 6).
Imaging and statistical analysis
Images were acquired using a charge-coupled device camera
(DFC320; Leica, Wetzlar, Germany). Brightness and contrast
were adjusted using FixFoto software (Joachim Koopmann
Software, Wrestedt, Germany). All figures and tables were
prepared using Microsoft Office Package 2010 (Microsoft,
Remond, WA, USA), or Adobe Creative Suite 5 (Adobe, San
Jose, CA, USA).
For statistical analysis a one-way ANOVA and Dunnett’s
multiple comparison test against healthy control group was
performed using GraphPad Prism 5 (GraphPad Software Inc.,










Age, years 62.6  14.47 68.0  5.93 67.1  6.59
Male/female 8/4 7/1 8/4
FEV1
(% predicted)
58.7  14.24 59.9  11.87 110.1  29.5
FEV1, forced expiratory volume in one second; data are pre-
sented as mean  SD.
590 F. Pedersen et al.La Jolla, CA, USA). For the comparison of the cellular
composition of HOPE-treated samples with the cytospin-
preparations we used the paired Wilcoxon Rank Sum Test.
Differences between groups were considered statistical
significant at a level of p < 0.05.Figure 1 Immunocytochemistry of HOPE-preserved paraffin-
embedded induced sputum (5 mm sections; healthy control):
(A) anti-CD68 detecting monocytes/macrophages, (B) anti-CD8
detecting lymphocytes. All images were taken at a magnifica-
tion of 400 (scale bar 50 mm) and using aminoethylcarbazole
as a chromogen (red signals).Results
Study population
33 patients (12 current smokers with COPD; 9 ex-smokers
with COPD; 12 healthy controls) of similar age were initially
included in this study (Table 1). For sputum analysis one
COPD patient of the ex-smoker group was excluded due to
coexisting pulmonary asbestosis, which might impact
molecular analysis.
Cellular characteristics of induced sputum samples
The mean concentration of total cell counts was 2.57  106
cells/ml in current smokers with COPD, 2.29  106 cells/ml
in ex-smokers with COPD, and 2.05  106 cells/ml in
healthy subjects (Table 2). Total cell counts were not
significantly different between groups. Differential cell
counts of induced sputum samples in the COPD smoker and
the COPD-ex-smoker group revealed a significantly higher
relative amount of neutrophil granulocytes compared to
healthy subjects (Table 2). Contrary, the relative number
of macrophages was significantly lower in the COPD
smoker and COPD-ex-smoker group compared to healthy
controls (Table 2). No significant differences were
detectable on the relative amount of lymphocytes,Table 2 Cellular characteristics of induced sputum samples.
TCC [106/ml] Via [%] SM [%]
COPD (Smoker) 2.57  3.74 95.41  3.44 14.48  7.09**
COPD (Ex-smoker) 2.29  1.12 95.70  2.91 15.10  9.69**
Healthy control 2.05  1.35 95.23  2.65 30.81  11.84
TCC, total cell count; Via, viability; SM, sputum macrophages; N
lymphocytes; BEC, bronchial epithelial cells. Differential cell counts w
calculated as percentage of non-squamous cells. Data are presented
***: p < 0.001, **: p < 0.01 by one-way ANOVA and Dunnett’s multipleosinophil granulocytes, and bronchial epithelial cells.
The average contamination of squamous cells was
10.62  11.53 in the COPD smoker, 8.8  7.03 in the COPD-
ex-smoker, and 7.6  5.15% in the healthy control group.
The average viability in all groups exceeded 95% (Table 2).
A comparison of the cellular composition of the fresh
whole cell preparations with the sections of HOPE-
preserved and Giemsa stained sputum cell pellets
revealed differences regarding the percentages of
macrophages, whereas the percentages of neutrophil
granulocytes were not significantly different between both
preparations (supplemental material S3).NG [%] EOS [%] LY [%] BEC [%]
* 82.98  8.54*** 0.75  1.01 0.68  0.57 1.14  1.23
80.58  10.26** 1.38  1.91 1.25  0.66 1.69  1.42
65.12  13.55 0.23  0.29 2.11  2.58 1.73  1.79
G, neutrophil granulocytes; EOS, eosinophil granulocytes; LY,
ere made on fresh whole cell preparations (cytoslides) and were
as mean  SD.
e comparison test against healthy control.
Figure 2 Immunocytochemistry of HOPE-preserved paraffin-embedded induced sputum (5 mm sections). Examples of inflam-
matory markers in the sputum of one healthy subject: interleukin-8 (A); myeloperoxidase (B); interleukin-17 (C);
matrixmetalloproteinase-9 (D). All images were taken at a magnification of 400x (scale bar 50 mm) using aminoethylcarbazole as
a chromogen (red signals). Signals were observed in sputum macrophages and neutrophil granulocytes.
Figure 3 Electropherograms of HOPE-preserved sputum RNA samples isolated with the Qiagen RNeasy kit. Electrophoresis was
performed in an Agilent 2100 Bioanalyzer using the RNA 6000 Nano kit with eukaryotic total RNA Nano assay. The electrophe-
rograms reveal fluorescence intensity [FU] versus size of the total RNA [nt]. RNA quality of all HOPE-preserved sputum samples that
were pooled for transcription analysis is comparable.
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Figure 4 Electropherograms of formalin-fixed (A, D), HOPE-preserved (B, E), and fresh-frozen sputum RNA samples. X-coordi-
nate, time in seconds [s]; y-coordinate, fluorescence intensity [FU].
Figure 5 Electropherograms showing the reproducibility of the RNA quality from three HOPE-preserved sputum portions from the
same sputum sample. X-coordinate, time in seconds [s]; y-coordinate, fluorescence intensity [FU].
592 F. Pedersen et al.Morphology and immunostaining of HOPE-
preserved induced sputum samples
In order to assess the value of HOPE-preservation of
induced sputum samples sections of paraffin blocks were
immunocytochemically stained for cell surface markers as
well as inflammatory biomarkers. On neither of these
stainings, an antigen retrieval was performed. Altogether,
the results revealed good morphology of the induced
sputum cells preserved with the HOPE-technique. Immune
detection of monocytes/macrophages via anti-CD68 stain-
ing (Fig. 1A) as well as lymphocytes via anti-CD8 staining
(Fig. 1B) was possible. Furthermore, the immunocyto-
chemical staining of interleukin-8, myeloperoxidase,
interleukin-17, and matrixmetalloproteinase-9 was feasible
and revealed clear staining in all HOPE-preserved induced
sputum cells (Fig. 2).Table 3 The transcriptome analysis of the HOPE-preserved ind
Total number of do
genes [Log2]
<2.1 2.1e
COPD (smoker) vs. healthy 4419 3864
COPD (smoker) vs. COPD (ex-smoker) 4499 1543
COPD (ex-smoker) vs. healthy 3849 521
Quantile normalized data are shown using DirectArray software.RNA quality
After extraction of total RNA, integrity and yield of all
samples were assessed and exhibited well preserved RNA
suitable for transcriptome analysis (Fig. 3). The RNA purity
of the pooled samples assessed by the OD 260/280 nm ratio
was 2.48 (healthy group), 2.41 (COPD smoker) and 2.60
(COPD ex-smoker).
The comparison of the HOPE-preserved sputum samples
with the formalin-fixed samples and the fresh-frozen
samples showed a similar purity of RNA of the HOPE-
treated and fresh-frozen samples, whereas the formalin-
fixed samples were unsuitable for transcription microarray
analysis (Fig. 4, supplemental material S4). The reproduc-
ibility of RNA purity assed by OD 260/280 was 1.82  0.01
(mean  SD). Reproducibility of RNA integrity and RNA
concentration are shown in Fig. 5.uced sputum cells.
wn-regulated Total number of up-regulated genes
[Log2]
4.0 >4.0 <2.1 2.1e4.0 >4.0
374 6768 4681 49
73 6469 897 24
7 5171 555 20
Figure 6 Transcriptome analysis of RNA samples from HOPE-
sputum. Agilent 4x44k human whole genome arrays have been
used. Analysis of the results was performed using GeneSpring
12 software. Hierarchical clustering of baseline transformed
transcriptome raw data clustering healthy controls with COPD
ex-smokers and COPD smokers, respectively. Three groups are
compared (Healthy, COPD Ex-smoker, COPD Smoker). Red color
indicates high expression, green color indicates low expres-
sion, and white color indicates a medium level of expression of
a gene in the comparison of the three groups.
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preserved induced sputum samples
In addition to immunocytochemical analysis we also applied
a transcriptome analysis. The amount and concentration of
isolated RNA were adequate to pool samples of four or five
patients of each group for differential gene expression
analysis on the Agilent Whole Human Genome microarray
4x44k (supplemental material S2).
The quantile normalized raw data signals were
compared between the three different groups. The total
number of down- and up-regulated genes differed
substantially between groups (Table 3). The most striking
differences could be observed comparing the COPD smoker
group with healthy subjects. A number of 4419 genes were
significantly down-regulated whereas 6768 genes were
significantly up-regulated in COPD smoker when compared
to healthy controls (Table 3). Based on a Log2fold-change
of more than 4 there were 374 genes significantly up-
regulated and 49 genes significantly down-regulated
comparing these two groups (Table 3).
A clear effect of smoking on the number of down- and
up-regulated genes could also be observed when comparing
COPD smokers with COPD ex-smokers (Table 3).
Hierarchical clustering of baseline transformed raw data
(41067 different entities) revealed also a higher similarity
between COPD ex-smokers and smokers, when compared to
healthy controls (Fig. 6).
Altogether, we identified distinct clusters of genes which
are differentially regulated by disease state and smoking
status.
Discussion
The present study demonstrates that the HOPE-technique
with subsequent morphological and molecular-biological
analyses can be applied on induced sputum samples. As
already shown for tissues and bronchoalveolar lavage cells,
this technique with paraffin-embedding will improve the
long-term storage of induced sputum samples at high
quality level and represents a promising tool for the
establishment of biobanks in respiratory diseases using
induced sputum samples.13,16
Preservation of tissue with HOPE has been shown to
represent an appropriate and simple technique for
analyzing tissue.9,18 In particular, in situ hybridization,14
immunocytochemistry without antigen retrieval,15 tissue
microarray analysis19 as well as laser microdissection20 have
been successfully performed in HOPE-treated preparations.
Moreover, we recently applied HOPE to bronchoalveolar
lavage cells and demonstrated its practicability for
biomarker detection by using genomic and proteomic
approaches.16
Bronchoalveolar lavage supports clinical diagnosing and
displays a useful tool for research on cellular responses
and characteristics during airway inflammation.21 The
invasiveness of bronchoscopy, however, makes bron-
choalveolar lavage less feasible for large scale-diagnostics
or follow-up investigations. Contrary to this, induced
sputum offers a well-tolerated and non-invasive method
that allows repeated analysis to monitor the course of
594 F. Pedersen et al.disease.22,23 However, contrary to bronchoalveolar lavage,
induced sputum requires a time-consuming processing
procedure within 2 h after expectoration.24 This includes
homogenization by DTT-treatment followed by a filtration
step. Subsequently, viability and total cell counts as well
as differential cell counts are mostly evaluated.24,1 For
sample storage, induced sputum samples are usually either
fixed with PFA or frozen at 20 C or 80 C after addition
of dimethyl sulfoxide (DMSO) which avoids water crystal-
lization.25 Although PFA-fixation obtains good morphology,
a later molecular-biological analysis due to cross-linking of
protein antigens is hampered. By contrast, freezing allows
a delayed biomarker analysis but complicates morpholog-
ical investigations. Moreover, the addition of DMSO is
assumed to influence RNA integrity.26 Preservation of
induced sputum samples using HOPE combines the benefits
of both methods. Altogether, our results revealed good
morphology of induced sputum cells.
Furthermore, we were able to detect and localize
biomarkers including interleukin-8, interleukin-17, mye-
loperoxidase, and matrixmetalloproteinase-9 by immuno-
cytochemistry without antigen retrieval. Besides
preservation of proteins, it was also possible to extract
RNA suitable for microarray analysis of the HOPE-
preserved induced sputum samples. As a result, we
revealed clear differences in gene expression profiles
between all groups. As expected, this became especially
apparent when comparing current smokers with COPD and
healthy subjects.
In contrast to bronchoalveolar lavage,16 the preparation
of sections with less than 5 mm thickness was hardly
achievable in paraffin-embedded induced sputum speci-
mens due to their small size and softness. A possible
explanation for this effect is the use of DTT for mucus
removal and cell homogenization during processing.
However, the benefits of the HOPE-technique for sputum
samples, notably the preservation of proteins and nucleic
acids, outweigh this minor drawback. Furthermore, the
HOPE-technique with subsequent paraffin-embedding for
long-term storage offers the chance to expand the read out
options in biobanks. In combination with the non-invasive
way of collection, the presented technique might provide
a great opportunity to identify new biomarkers and thera-
peutic targets not only in COPD, but also in other lung
diseases like asthma and cystic fibrosis.
We conclude that sputum samples preserved by the
HOPE-technique display a useful tool to address scientific
approaches in pulmonary research, which can enable the
identification of new biomarkers and therapeutic targets in
respiratory diseases.Acknowledgments
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